In a bid to reduce the state’s expenditure on employee prescription costs, Maryland has introduced a new pharmacy benefits contract. Despite high expectations, the contract is projected to yield only modest savings in its initial years. The contract, awarded to MedImpact Healthcare Systems, is valued at over $1.3 billion and includes options for extensions that could increase its total value to more than $2.4 billion. The savings are expected to grow over time, but the initial impact will be limited.
Modest Savings in Initial Years
The new contract is expected to save Maryland a modest amount in the first few years. According to Maryland Budget Secretary Helene Grady, the state will save about a million dollars in 2025, $12 million in 2026, and $22 million in 2027. These figures are significantly lower than the hundreds of millions initially anticipated. The contract was awarded through a reverse auction process, which typically helps lower costs by encouraging competitive bidding. However, only two qualified bidders participated, limiting the potential savings.
The current contract holder, CVS Caremark Health, filed an appeal after losing the contract. The appeal was dismissed due to a late filing, but CVS Caremark argued that the reverse auction process was flawed. They claimed that competitive bids were not objectively compared, leading to an unfair outcome. Despite these concerns, the new contract is set to proceed, with the state hoping for increased savings in the later years of the agreement.
Reverse Auction Process and Its Challenges
The reverse auction process used to award the contract is designed to drive down costs by having bidders compete to offer the lowest price. This method has been successful in other states, but in Maryland, it attracted only two qualified bidders. The limited competition may have contributed to the modest initial savings. Maryland officials remain optimistic that the savings will increase over time as the contract progresses.
CVS Caremark’s appeal highlighted potential issues with the reverse auction process. They argued that the state’s rollout of the new procurement method led to a situation where bids were not fairly compared. Despite these claims, the appeal was dismissed, and the new contract with MedImpact Healthcare Systems will move forward. The state is hopeful that the contract will eventually yield significant savings, even if the initial impact is modest.
Future Prospects and Expectations
While the initial savings from the new contract are modest, Maryland officials are optimistic about the future. The projected savings are expected to increase in the later years of the contract, providing more substantial financial benefits to the state. The contract includes options for two two-year extensions, which could extend its total duration to seven years and its value to over $2.4 billion.
The state is also exploring additional measures to reduce prescription costs for employees. These efforts include ongoing evaluations of the reverse auction process and potential adjustments to improve its effectiveness. Maryland remains committed to finding ways to lower healthcare costs and provide better value for its employees and retirees.
Comments